Patients News | pharmaphorum

News

After FDA nod, Eisai and Biogen file lecanemab in EU

Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer's therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in th

News

NICE backs "artificial pancreas" tech for type 1 diabetics

More than 100,000 people in England and Wales with type 1 diabetes that they find hard to control with current therapy could soon be offered new technology via the NHS.

News

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

News

Male doctor hands typing on laptop computer keyboard, search medical information with digital tablet pc and medical stethoscope on the desk at office. Online medical,medic tech, emr, ehr concept.

Google and DeepMind share work on medical chatbot Med-PaLM

Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate "safe and helpful answers" to questions posed by healthcare professio

News

Study shows there is still a long way to go on trial diversi...

It's no revelation that the pharma industry has often fallen short when it comes to making sure its clinical trial populations include representation of racial and ethnic minorities, but a

News

Closeup of X-ray photography of human brain

Eisai questions link between lecanemab and patient death

With the FDA due to deliver a decision of Eisai and Biogen's new Alzheimer's disease candidate lecanemab tomorrow, the safety of the drug has been thrust into the spotlight by a case report

After FDA nod, Eisai and Biogen file lecanemab in EU

NICE backs "artificial pancreas" tech for type 1 diabetics

Free access to Zolgensma curbed, says Novartis

Google and DeepMind share work on medical chatbot Med-PaLM

Study shows there is still a long way to go on trial diversi...

Eisai questions link between lecanemab and patient death

FDA hands another rejection to Replimune's melanoma therapy

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks